Matt Miksic
Stock Analyst at Barclays
(3.73)
# 768
Out of 4,984 analysts
295
Total ratings
59.66%
Success rate
4.22%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SENS Senseonics Holdings | Initiates: Overweight | $1.5 | $0.45 | +235.20% | 1 | Aug 27, 2025 | |
| HUMA Humacyte | Initiates: Overweight | $3.5 | $1.53 | +128.76% | 1 | Aug 27, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $55 → $58 | $54.53 | +6.36% | 8 | Aug 21, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $266 → $300 | $322.22 | -6.90% | 9 | Aug 21, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $53 → $51 | $12.18 | +318.72% | 7 | Aug 8, 2025 | |
| BAX Baxter International | Maintains: Overweight | $41 → $36 | $23.20 | +55.17% | 22 | Aug 4, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $21 → $22 | $14.70 | +49.66% | 3 | Aug 4, 2025 | |
| INMD InMode | Maintains: Overweight | $24 → $21 | $14.93 | +40.66% | 14 | Jul 30, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $93 → $98 | $76.44 | +28.21% | 7 | Jul 30, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $90 → $95 | $75.20 | +26.33% | 29 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $133 | $98.50 | +35.03% | 18 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $9 → $19 | $18.88 | +0.64% | 8 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $176 | $177.20 | -0.68% | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $19 → $16 | $15.12 | +5.82% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $187.57 | +28.49% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $2.46 | +387.80% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $433.66 | +46.43% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $134.17 | +18.51% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $56.22 | +83.21% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $99.92 | +12.09% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $376.88 | +17.54% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $5.61 | +292.16% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $94.58 | +15.25% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $77.20 | +24.35% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $67.37 | +48.43% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $129.44 | +222.93% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.25 | +72.31% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $13.43 | +398.88% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $6.18 | +7,666.99% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $14.80 | +487.84% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.62 | +441.13% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.94 | +29.68% | 1 | Dec 12, 2016 |
Senseonics Holdings
Aug 27, 2025
Initiates: Overweight
Price Target: $1.5
Current: $0.45
Upside: +235.20%
Humacyte
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.53
Upside: +128.76%
LivaNova
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $54.53
Upside: +6.36%
Insulet
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $266 → $300
Current: $322.22
Upside: -6.90%
Tandem Diabetes Care
Aug 8, 2025
Maintains: Overweight
Price Target: $53 → $51
Current: $12.18
Upside: +318.72%
Baxter International
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $23.20
Upside: +55.17%
Alphatec Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $14.70
Upside: +49.66%
InMode
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.93
Upside: +40.66%
DexCom
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $76.44
Upside: +28.21%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $90 → $95
Current: $75.20
Upside: +26.33%
Jul 24, 2025
Maintains: Overweight
Price Target: $125 → $133
Current: $98.50
Upside: +35.03%
Jul 22, 2025
Upgrades: Equal-Weight
Price Target: $9 → $19
Current: $18.88
Upside: +0.64%
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $177.20
Upside: -0.68%
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $15.12
Upside: +5.82%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $187.57
Upside: +28.49%
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.46
Upside: +387.80%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $433.66
Upside: +46.43%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $134.17
Upside: +18.51%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $56.22
Upside: +83.21%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $99.92
Upside: +12.09%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $376.88
Upside: +17.54%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $5.61
Upside: +292.16%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $94.58
Upside: +15.25%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $77.20
Upside: +24.35%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $67.37
Upside: +48.43%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $129.44
Upside: +222.93%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.25
Upside: +72.31%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $13.43
Upside: +398.88%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $6.18
Upside: +7,666.99%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $14.80
Upside: +487.84%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.62
Upside: +441.13%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.94
Upside: +29.68%